Vassallo RR Jr. New paradigms in the management of alloimmune refractoriness to platelet transfusions. Curr Opin Hematol 2007;14:655–63.10.1097/MOH.0b013e3282eec52617898571Search in Google Scholar
Seftel MD, Growe GH, Petraszko T, et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004;103:333–9.10.1182/blood-2003-03-094012958065Search in Google Scholar
Kerkhoffs JL, Eikenboom JC, van de Watering LM, et al. The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion 2008;48:1959–65.10.1111/j.1537-2995.2008.01799.x18564396Search in Google Scholar
Doughty HA, Murphy MF, Metcalfe P, et al. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994;66:200–5.10.1111/j.1423-0410.1994.tb00310.x8036790Search in Google Scholar
Slichter SJ, Davis K, Enright H, et al. Factors affecting posttranfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005;105:4106–14.10.1182/blood-2003-08-2724189507615692069Search in Google Scholar
Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol 2008;142:348–60.10.1111/j.1365-2141.2008.07189.x18510692Search in Google Scholar
Daly PA, Schiffer CA, Aisner J, Wiernik PH. Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations. JAMA 1980; 243:435–8.10.1001/jama.1980.03300310023016Search in Google Scholar
Yankee RA, Grumet FC, Rogentine GN. Platelet transfusion: the selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing. N Engl J Med 1969;281:1208–12.10.1056/NEJM1969112728122025347838Search in Google Scholar
The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337:1861–9.10.1056/NEJM1997122533726019417523Search in Google Scholar
AuBuchon JP, Leach MF. Investigating the possibility of drug-dependent platelet antibodies. Immunohematology 2009;25:136–140.10.21307/immunohematology-2019-246Search in Google Scholar
Cooling L. ABO and platelet transfusion therapy. Immunohematology 2007;23:20–33.10.21307/immunohematology-2019-314Search in Google Scholar
[No authors listed.] Detection of platelet-reactive antibodies in patients who are refractory to platelet transfusions, and the selection of compatible donors. Vox Sang 2003;84:73–88.10.1046/j.1423-0410.2003.00259.xSearch in Google Scholar
Heal JM, Blumberg N, Masel D. An evaluation of cross-matching, HLA and ABO matching for platelet transfusions to refractory patients. Blood 1987;60:23–30.10.1182/blood.V70.1.23.23Search in Google Scholar
Petz LD. The HLA system and platelet transfusion. In: Murphy S, ed. The HLA system: basic biology and clinical applications. Bethesda, MD: American Association of Blood Banks, 1999.Search in Google Scholar
Curtis BR, McFarland JG. Detection and identification of platelet antibodies and antigens in the clinical laboratory. Immunohematology 2009;25:125–135.10.21307/immunohematology-2019-245Search in Google Scholar
Semana G, Zazoun T, Alizahed M, et al. Genetic susceptibility and anti-human platelet antigen 5b alloimmunization: role of class II and TAP genes. Hum Immunol 1996;46:114–19.10.1016/0198-8859(96)00019-5Search in Google Scholar
Blanchette VS, Chen L, de Friedberg ZS, et al. Alloimmunization to the PlA1 platelet antigen: results of a prospective study. Br J Haematol 1990;74:209–15.10.1111/j.1365-2141.1990.tb02567.x2317456Search in Google Scholar
Norton A, Allen DL, Murphy MF. Review: platelet alloantigens and antibodies and their clinical significance. Immunohematology 2004;20:89–102.10.21307/immunohematology-2019-430Search in Google Scholar
Curtis BR, Ali S, Glazier AM, et al. Isoimmunization against CD36 (glycoprotein IV): description of four cases of neonatal alloimmune thrombocytopenia and brief review of the literature. Transfusion 2002;42:1173–9.10.1046/j.1537-2995.2002.00176.x12430674Search in Google Scholar
Taaning E, Sinonsen AC, Hjelms E, et al. Platelet alloimmunization after transfusion. Vox Sang 1997;72:238–41.10.1159/000462001Search in Google Scholar
Kiefel V, Konig C, Kroll H, Santoso S. Platelet alloantibodies in transfused patients. Transfusion 2001;41:766–70.10.1046/j.1537-2995.2001.41060766.x11399817Search in Google Scholar
Kickler T, Kennedy SD, Braine HG. Alloimmunization to platelet-specific antigens on glycoproteins IIb-IIIa and Ib/IX in multiply transfused thrombocytopenic patients. Transfusion 1990;30:622–5.10.1046/j.1537-2995.1990.30790385520.x2402776Search in Google Scholar
Legler TJ, Fischer I, Dittmann J, et al. Frequency and causes of refractoriness in multiply transfused patients. Ann Hematol 199;74:185–9.10.1007/s0027700502809174547Search in Google Scholar
Kurz M, Greinix H, Hocker P, et al. Specificities of anti-platelet antibodies in multitransfused patients with haemato-oncological disorders. Br J Haematol 1996;95:564–9.10.1046/j.1365-2141.1996.d01-1936.x8943903Search in Google Scholar
Godeau B, Fromont P, Seror T, et al. Platelet alloimmunization after multiple transfusions: a prospective study of 50 patients. Br J Haematol 1992;81:395–400.10.1111/j.1365-2141.1992.tb08246.x1390213Search in Google Scholar
Uhrynowska M, Zupanska B. Platelet-specific antibodies in transfused patients. Eur J Haematol 1996;56:248–51.10.1111/j.1600-0609.1996.tb01937.x8641394Search in Google Scholar
McGrath K, Wolf M, Bishop J, et al. Transient platelet and HLA antibody formation in multitransfused patients with malignancy. Br J Haematol 1988;68:345–50.10.1111/j.1365-2141.1988.tb04212.x3355793Search in Google Scholar
Murphy MF, Metcalfe P, Ord J, et al. Disappearance of HLA and platelet-specific antibodies in acute leukaemia patients alloimmunized by multiple transfusions. Br J Haematol 1987;67:255–60.10.1111/j.1365-2141.1987.tb02344.x3689693Search in Google Scholar
McFarland JG. Alloimmunization and platelet transfusion. Semin Hematol 1996;33:315–28.Search in Google Scholar
Schnaidt M, Northoff H, Wernet D. Frequency and specificity of platelet-specific alloantibodies in HLA-immunized haematologic-oncologic patients. Transfus Med 1996;6:111–14.10.1046/j.1365-3148.1996.d01-58.x8809957Search in Google Scholar
Sanz C, Freire C, Alcorta I, et al. Platelet-specific antibodies in HLA-immunized patients receiving chronic platelet support. Transfusion 2001;41:762–5.10.1046/j.1537-2995.2001.41060762.x11399816Search in Google Scholar
Pappalardo PA, Secord AR, Quitevis P, et al. Platelet transfusion refractoriness associated with HPA-1a (PlA1) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions. Transfusion 2001;41:984–7.10.1046/j.1537-2995.2001.41080984.x11493728Search in Google Scholar
Fujino H, Ohta K, Taniue A, et al. Primary refractoriness to platelet transfusion caused by Naka antibody alone. Vox Sang 2001;81:42–4.10.1046/j.1423-0410.2001.00048.x11520415Search in Google Scholar
Lo SC, Chang JS, Lin SW, Lin DT. Platelet alloimmunization after long-term red cell transfusion in transfusion-dependent thalassemia patients. Transfusion 2005;45:761–5.10.1111/j.1537-2995.2005.04246.x15847666Search in Google Scholar
Ertel K, Al-Tawil M, Santoso S, Kroll H. Relevance of the HPA-15 (Gov) polymorphism on CD109 in alloimmune thrombocytopenic syndromes. Transfusion 2005;45:366–73.10.1111/j.1537-2995.2005.04281.x15752154Search in Google Scholar
Berry JE, Murphy CM, Smith GA, et al. Detection of Gov system antibodies by MAIPA reveals an immunogenicity similar to the HPA-5 alloantigens. Br J Haematol 2000;110:735–42.10.1046/j.1365-2141.2000.02170.x10997989Search in Google Scholar
Semple JW, Speck ER, Milev YP, et al. Indirect allorecognition of platelet by T helper cells during platelet transfusions correlates with anti-major histocompatibility complex antibody and cytotoxic T lymphocyte formation. Blood 1995; 86:805–12.10.1182/blood.V86.2.805.bloodjournal862805Search in Google Scholar
Sayeh E, Aslam R, Speck ER, et al. Immune responsiveness against allogeneic platelet transfusions is determined by the recipient’s major histocompatibility complex class II phenotype. Transfusion 2004;44:1572–8.10.1111/j.1537-2995.2004.04197.x15504162Search in Google Scholar
Lucas GF, Rogers SE. Evaluation of an enzyme-linked immunosorbent assay kit (GTi PakPlus) for the detection of antibodies against human platelet antigens. Transfus Med 1999;9:63–7.10.1046/j.1365-3148.1999.009001063.x10216906Search in Google Scholar
Allen D, Ouwehand WH, de Haas M, et al. Interlaboratory variation in the detection of HPA-specific alloantibodies and in molecular HPA typing. Vox Sang 2007;93:316–24.10.1111/j.1423-0410.2007.00960.x18070276Search in Google Scholar
Lucas GF, Metcalfe P. Platelet and granulocyte glycoprotein polymorphisms. Transfus Med 2000;10:157–74.10.1046/j.1365-3148.2000.00250.x10972910Search in Google Scholar
Cserti-Gazdewich CM, Dzik WH, Dorn ME, et al. Quantitation of CD36 (platelet glycoprotein IV) expression on platelets and monocytes by flow cytometry: application to the study of Plasmodium falciparum malaria. Cytometry B Clin Cytom 2009;76:127–34.10.1002/cyto.b.2044318671254Search in Google Scholar
